At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 71 enrolled
Drug / intervention
Canagliflozin (TA-7284) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Canagliflozin (TA-7284) and GLP-1 analogue for Type 2 Diabetes Mellitus. Completed, enrolled 71 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedAug 2014
Primary CompletionMar 2016
TodayJul 2026
First PostedAug 28, 2014
Enrollment StartAug 1, 2014
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.8 years ago
Interventions
Canagliflozin (TA-7284)drug
The patients will receive Canagliflozin orally for 52 weeks
GLP-1 analoguedrug